I6T-MC-AMAP: A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507657-15-00

Acronym

I6T-MC-AMAP

Enrollment

298

Registered

2023-11-29

Start date

2018-09-13

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

Percentage of participants in clinical remission. Clinical remission is based on the modified Mayo Score (MMS).

Detailed description

Percentage of participants in endoscopic remission, based on the Mayo Endoscopic Score (ES)., Percentage of participants who are hospitalized due to UC over time., Percentage of participants who undergo UC surgeries over time., IBDQ scores over time

Interventions

DRUGMirikizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of participants in clinical remission. Clinical remission is based on the modified Mayo Score (MMS).	—

Secondary

Measure	Time frame
Percentage of participants in endoscopic remission, based on the Mayo Endoscopic Score (ES)., Percentage of participants who are hospitalized due to UC over time., Percentage of participants who undergo UC surgeries over time., IBDQ scores over time	—

Countries

Austria, Belgium, Czechia, Denmark, France, Hungary, Italy, Latvia, Lithuania, Netherlands, Poland, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026